These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38139457)

  • 1. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
    Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
    Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
    NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
    Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
    Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GBM Tumor Microenvironment as a Modulator of Therapy Response: ADAM8 Causes Tumor Infiltration of Tams through HB-EGF/EGFR-Mediated CCL2 Expression and Overcomes TMZ Chemosensitization in Glioblastoma.
    Liu X; Huang Y; Qi Y; Wu S; Hu F; Wang J; Shu K; Zhang H; Bartsch JW; Nimsky C; Dong F; Lei T
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of the tumor microenvironment in glioblastoma patients: correlation of microglia/macrophage polarization state with metalloprotease expression profiles and survival.
    Gjorgjevski M; Hannen R; Carl B; Li Y; Landmann E; Buchholz M; Bartsch JW; Nimsky C
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31142630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
    Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
    Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide.
    Lee GA; Lin WL; Kuo DP; Li YT; Chang YW; Chen YC; Huang SW; Hsu JB; Chen CY
    Int J Nanomedicine; 2021; 16():5233-5246. PubMed ID: 34366665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
    BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
    Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
    ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity.
    Liu CC; Yang WB; Chien CH; Wu CL; Chuang JY; Chen PY; Chu JM; Cheng SM; Qiu LY; Chang YC; Hwang DY; Huang CY; Lee JS; Chang KY
    Cell Death Dis; 2024 Jun; 15(6):434. PubMed ID: 38898023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma.
    Kuang RZ; Wang J; Wang YC; Tang XP
    Clinics (Sao Paulo); 2024; 79():100376. PubMed ID: 38733690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
    Wu S; Calero-Pérez P; Arús C; Candiota AP
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
    Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
    Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
    Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
    Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
    Li J; Kaneda MM; Ma J; Li M; Shepard RM; Patel K; Koga T; Sarver A; Furnari F; Xu B; Dhawan S; Ning J; Zhu H; Wu A; You G; Jiang T; Venteicher AS; Rich JN; Glass CK; Varner JA; Chen CC
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.